USPTO Art Unit 1641 Prosecution Statistics

Art Unit Information

Art Unit: 1641
Group: 1640
Tech Center: 1600
Total Cases: 10,233
Last Active: March 2025

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
19074158PLATELET DERIVATIVE COMPOSITIONS, AND PLURALITIES OF CONTAINERS CONTAINING SAMEMarch 2025April 2025Allow200NoNo
19026296MRNA VACCINE ENCODING FUSION ANTIGEN AGAINST MPOX AND SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2January 2025April 2025Allow300YesNo
19003301BISPECIFIC CHIMERIC ANTIGEN RECEPTORS TARGETING CD20 AND BCMADecember 2024April 2025Allow300YesNo
18988307HUMANIZED ANTIBODIES AGAINST IRHOM2December 2024March 2025Allow300YesNo
18980920FCRN/HSA BINDING MOLECULES AND METHODS OF USEDecember 2024May 2025Allow501NoNo
18977144NOVEL ANTIGEN BINDING MOLECULE FORMATSDecember 2024April 2025Allow410NoNo
18962263ANTI-S100A4 HUMANIZED ANTIBODIES, USES AND METHODSNovember 2024April 2025Allow411NoNo
18945784Antibodies Targeting ActRIIA and ActRIIBNovember 2024February 2025Allow310NoNo
18922371METHODS FOR TREATMENT USING ANTI-ALPHA4BETA7 ANTIBODYOctober 2024March 2025Allow510YesNo
18920412ANTI-PHOSPHOCHOLINE ANTIBODIES AND METHODS OF USE THEREOFOctober 2024March 2025Allow501YesNo
18895539HEPARANASE-NEUTRALIZING A54 MONOCLONAL ANTIBODYSeptember 2024June 2025Allow810YesNo
18850224PEPTIDE USEFUL FOR THE TRANSPORT OF MOLECULES THROUGH CELL BARRIERSSeptember 2024June 2025Allow910NoNo
18817152PROTEIN S ANTIBODIES, METHODS OF MAKING AND USES THEREOFAugust 2024May 2025Allow911NoNo
18815390FUSION PROTEIN COMPRISING ANTI-CD73 ANTIBODY AND IL-2, AND USE THEREOFAugust 2024May 2025Allow911YesNo
18810381METHODS USING FREEZE-DRIED PLATELET DERIVATIVE COMPOSITIONS FOR RESTORING HEMOSTASIS IN A SUBJECTAugust 2024February 2025Allow611YesNo
18774608COMPOSITIONS AND METHODS FOR TREATING SYNUCLEINOPATHIESJuly 2024January 2025Allow610YesNo
18774646COMPOSITIONS AND METHODS FOR TREATING SYNUCLEINOPATHIESJuly 2024April 2025Allow920YesNo
18774629COMPOSITIONS AND METHODS FOR TREATING SYNUCLEINOPATHIESJuly 2024March 2025Allow820YesNo
18773400VIVO GENE THERAPY USING INTRAOSSEOUS DELIVERY OF A LENTIVIRALGENE CONSTRUCTJuly 2024June 2025Allow1120YesNo
18770102PHOSPHO-TAU ANTIBODIES AND METHODS OF USEJuly 2024March 2025Allow811YesNo
18750999PLK1 INHIBITOR IN COMBINATION WITH ANTI-ANGIOGENICS FOR TREATING METASTATIC CANCERJune 2024June 2025Abandon1201NoNo
18750887PLK1 INHIBITOR IN COMBINATION WITH ANTI-ANGIOGENICS FOR TREATING METASTATIC CANCERJune 2024June 2025Abandon1201NoNo
18750908PLK1 INHIBITOR IN COMBINATION WITH ANTI-ANGIOGENICS FOR TREATING METASTATIC CANCERJune 2024April 2025Abandon1010NoNo
18745750ANTI-RECEPTOR EXPRESSED ON LYMPHOID TISSUES (RELT) RECOMBINANT MONOCLONAL ANTIBODY AND PREPARATION METHOD AND USE THEREOFJune 2024November 2024Allow510YesNo
18733287Anti-DLL3 Antibodies and Uses ThereofJune 2024April 2025Allow1101YesNo
18677564ANTIBODY-DRUG CONJUGATES TARGETING FOLATE RECEPTOR ALPHA AND METHODS OF USEMay 2024May 2025Allow1212NoNo
18664070BINDING AGENTS TARGETING TROP2-EXPRESSING TUMOR CELLSMay 2024March 2025Allow1020NoNo
18664091BINDING AGENTS TARGETING TROP2-EXPRESSING TUMOR CELLSMay 2024December 2024Allow710NoNo
18664201VARIANT NUCLEIC ACID LIBRARIES FOR CORONAVIRUSMay 2024January 2025Allow800YesNo
18660156MODIFIED IMMUNOGLOBULINS FOR TARGETING AMYLOID DEPOSITSMay 2024July 2024Allow200NoNo
18660162MODIFIED IMMUNOGLOBULINS FOR TARGETING AMYLOID DEPOSITSMay 2024January 2025Allow920YesNo
18640981NOVEL ANTIGEN BINDING MOLECULE FORMATSApril 2024February 2025Allow1011YesNo
18627754Anti-SIRPa Antibodies and Methods of Use ThereofApril 2024November 2024Allow700NoNo
18607180ANTIBODY CAPABLE OF BINDING TO THYMIC STROMAL LYMPHOPOIETIN AND USE THEREOFMarch 2024August 2024Allow510NoNo
18601952ANTIBODIES WHICH BIND HUMAN FIBRIN OR FIBRINOGEN yC DOMAIN AND METHODS OF USEMarch 2024December 2024Allow920NoNo
18599751PHOSPHO-TAU ANTIBODIES AND METHODS OF USEMarch 2024February 2025Allow1110YesNo
18598342ANTI-CD45 ANTIBODIES AND CONJUGATES THEREOFMarch 2024August 2024Allow610NoNo
18597624REGIMENS AND METHODS OF TREATING MULTIPLE SCLEROSIS USING OFATUMUMABMarch 2024February 2025Allow1111YesNo
18588667COMPOSITIONS AND METHODS OF TREATING SARCOMA LUNG METASTASISFebruary 2024May 2025Abandon1510NoNo
18585676COMPOSITIONS AND METHODS COMPRISING ANTIBODIES THAT BIND TO COVALENT PEPTIDE CONJUGATESFebruary 2024April 2025Allow1421YesNo
18444471COMPOSITIONS COMPRISING PHARMACEUTICALLY ACCEPTABLE SALTS OF AMYLIN ANALOGS AND USES THEREOFFebruary 2024November 2024Allow911YesNo
18442779CD123 BINDING PROTEINS AND RELATED COMPOSITIONS AND METHODSFebruary 2024June 2025Allow1610NoNo
18440895Fc VARIANTS WITH ALTERED BINDING TO FcRnFebruary 2024June 2024Abandon400NoNo
18440437SPECIFIC BINDING MOLECULESFebruary 2024March 2025Allow1310NoNo
18439344Nano-sized Chitosan/VS2 nanocomposite like flowers for Antimicrobial ApplicationsFebruary 2024November 2024Allow911YesNo
18439336Method for Making Nano-sized Chitosan/VS2 NanocompositesFebruary 2024October 2024Allow820NoNo
18457687IMMUNOSILENCING Fc VARIANTSFebruary 2024June 2025Abandon2121NoNo
18427623High Efficiency Methods for Isolating ProteinsJanuary 2024May 2025Abandon1510NoNo
18420507SINGLE DOMAIN ANTIBODIES TO INFLUENZA HEMAGGLUTININ A AND BJanuary 2024April 2024Allow301YesNo
18414799COMPLEMENT COMPONENT C5 ANTIBODIESJanuary 2024April 2025Abandon1510NoNo
18408259CHIMERIC ANTIGEN RECEPTOR COMPOSITIONS AND METHODS FOR TREATING MUC1* DISEASESJanuary 2024July 2024Abandon611NoNo
18408386NUCLEIC ACIDS, VECTORS, AND CELLS THAT ENCODE ANTI-SP17 ANTIBODIES AND OTHER SP17 BINDING PROTEINSJanuary 2024October 2024Allow930NoNo
18403218INHIBITORS OF COMPLEMENT FACTOR HJanuary 2024December 2024Allow1211YesNo
18403419ANTIBODY SPECIFIC TO SPIKE PROTEIN OF SARS-COV-2 AND USES THEREOFJanuary 2024July 2024Allow610YesNo
18399934Novel Anti-Sema3a Antibodies And Uses ThereofDecember 2023August 2024Allow710NoNo
18394365TREATMENT OF CARDIOMETABOLIC DISEASE WITH INHIBITORS OF TYPE I INTERFERON SIGNALLINGDecember 2023May 2025Allow1721YesNo
18395074IMMUNOTHERAPEUTIC MOLECULES AND USES THEREOFDecember 2023April 2025Abandon1510NoNo
18389748ANTI-KLK7 ANTIBODIES, ANTI-KLK5 ANTIBODIES, MULTISPECIFIC ANTI-KLK5/KLK7 ANTIBODIES, AND METHODS OF USEDecember 2023February 2025Allow1401NoNo
18542031PEPTIDES AND METHODS FOR THE TREATMENT OF NEUROMYELITIS OPTICADecember 2023December 2024Abandon1201NoNo
18523196ANTIBODIES DIRECTED TO CLAUDIN 6, INCLUDING BISPECIFIC FORMATS THEREOFNovember 2023May 2024Allow511YesNo
18515714ANTIBODIES THAT BIND TO C1S AND USES THEREOFNovember 2023April 2024Allow501YesNo
18511744INTERFERON BETA ANTIBODIES AND USES THEREOFNovember 2023June 2025Allow1930NoNo
18507324Nano-sized Chitosan/VS2 nanocomposite like flowers for Potential Pharmaceutical ApplicationsNovember 2023July 2024Allow921YesNo
18506872PROTEIN S ANTIBODIES, METHODS OF MAKING AND USES THEREOFNovember 2023July 2024Allow811YesNo
18501413ANTIBODY VARIABLE DOMAINS TARGETING THE NKG2D RECEPTORNovember 2023January 2024Allow300NoNo
18501419ANTIBODY VARIABLE DOMAINS TARGETING THE NKG2D RECEPTORNovember 2023June 2024Allow820YesNo
18501427ANTIBODY VARIABLE DOMAINS TARGETING THE NKG2D RECEPTORNovember 2023July 2024Allow920YesNo
18384223ANTIBODIES RECOGNIZING SORTILINOctober 2023April 2024Allow510NoNo
18494454VARIANT IgG FC POLYPEPTIDES AND USES THEREOFOctober 2023March 2024Allow401NoNo
18492125PLK1 INHIBITOR IN COMBINATION WITH ANTI-ANGIOGENICS FOR TREATING METASTATIC CANCEROctober 2023January 2025Abandon1521YesNo
18486644ANTI-HUMAN MASP-2 ANTIBODY, PREPARATION METHOD THEREFOR AND APPLICATION THEREOFOctober 2023August 2024Allow1021NoNo
18486053ANTI-IGE ANTIBODY THERAPY FOR MULTIPLE FOOD ALLERGIESOctober 2023May 2024Allow711YesNo
18486137ANTIBODIES TO 25-HYDROXYVITAMIN D2 AND D3 FOR DETECTING TOTAL 25-HYDROXYVITAMIN DOctober 2023May 2025Allow1910NoNo
18481529COMPOSITIONS AND METHODS FOR TREATMENT OF CHRONIC LUNG DISEASESOctober 2023August 2024Allow1021YesNo
18480153TNF-ALPHA IMMUNOCONJUGATE THERAPY FOR THE TREATMENT OF BRAIN TUMORSOctober 2023March 2025Allow1810YesNo
18376135NANOEMULSION COMPOSITIONS FOR PREVENTING, SUPPRESSING OR ELIMINATING ALLERGIC AND INFLAMMATORY DISEASEOctober 2023May 2025Allow1910YesNo
18372623FUSION PEPTIDE INHIBITORS OF HUMAN CORONAVIRUS 229ESeptember 2023February 2024Allow410YesNo
18372634FUSION PEPTIDE INHIBITORS OF HUMAN CORONAVIRUS 229ESeptember 2023July 2024Allow921NoNo
18472144MONOCLONAL ANTIBODY AGAINST HUMAN LAG-3, METHOD FOR PREPARING THE SAME, AND USE THEREOFSeptember 2023April 2025Allow1911YesNo
18469961HLA BINDING VACCINE MOIETIES AND USES THEREOFSeptember 2023March 2025Allow1820NoNo
18469947NATURAL KILLER (NK) CELL ENGAGERS BINDING TO NKp46 AND BCMA VARIANTS WITH FC-ENGINEERINGSeptember 2023August 2024Allow1111NoNo
18462987SOYBEAN ALLERGY ANTIGENSeptember 2023June 2025Allow2121NoNo
18459892THERAPEUTIC USE OF MITOCHONDRIA AND COMBINED MITOCHONDRIAL AGENTSSeptember 2023August 2024Allow1121YesNo
18240347BINDING PROTEINS TO THE HUMAN THROMBIN RECEPTOR, PAR4August 2023June 2025Allow2210NoNo
18458043TOLEROGENIC SYNTHETIC NANOCARRIERS FOR ALLERGY THERAPYAugust 2023June 2025Abandon2101NoNo
18451751ANTIBODIES TO TICAGRELOR AND METHODS OF USEAugust 2023April 2025Allow2000NoNo
18450194THERAPEUTIC ANTIBODIES THAT BIND TO THE SERINE PROTEASE DOMAIN OF MASP-2 AND USES THEREOFAugust 2023May 2024Allow921NoNo
18358738GENETICALLY MODIFIED HUMAN NATURAL KILLER CELL LINESJuly 2023May 2025Abandon2231NoNo
18356891Antigen Binding Molecules Targeting Thymic Stromal Lymphopoietin (TSLP)July 2023June 2024Allow1011NoNo
18356928Anti-Dectin-2 Antibodies and Methods of UsingJuly 2023February 2025Allow1900NoNo
18354934CD1a ANTIBODIES AND USES THEREOFJuly 2023June 2025Allow2211YesNo
18354611TREATING CANCER BY BLOCKING THE INTERACTION OF TIM-3 AND ITS LIGANDJuly 2023April 2025Abandon2110NoNo
18349027ANTI-C1S ANTIBODIES AND METHODS OF USE THEREOFJuly 2023April 2025Allow2211NoNo
18348060BISPECIFIC T CELL ACTIVATING ANTIGEN BINDING MOLECULESJuly 2023April 2024Abandon1000NoNo
18344711IL2RBETA/COMMON GAMMA CHAIN ANTIBODIESJune 2023June 2025Abandon2411NoNo
18341202ANTI-CD40L ANTIBODIES AND METHODS FOR TREATING CD40L-RELATED DISEASES OR DISORDERSJune 2023December 2024Allow1710YesNo
18341437COMPOSITIONS AND METHODS FOR TREATING SYNUCLEINOPATHIESJune 2023May 2024Allow1011YesNo
18340722ANTI-FcRn ANTIBODY OR ANTIGEN BINDING FRAGMENT THEREOF WITH IMPROVED STABILITYJune 2023January 2024Allow710YesNo
18338946ANTI-PAR-2 ANTIBODIES AND METHODS OF USE THEREOFJune 2023April 2025Allow2111YesNo
18333869METHODS FOR TARGETING THE IMMUNE CHECKPOINT PD1 PATHWAY FOR TREATING PULMONARY FIBROSISJune 2023February 2025Allow2011NoNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for art-unit 1641.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
171
Examiner Affirmed
112
(65.5%)
Examiner Reversed
59
(34.5%)
Reversal Percentile
59.7%
Higher than average

What This Means

With a 34.5% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is above the USPTO average, indicating that appeals have better success here than typical.

Strategic Value of Filing an Appeal

Total Appeal Filings
1107
Allowed After Appeal Filing
263
(23.8%)
Not Allowed After Appeal Filing
844
(76.2%)
Filing Benefit Percentile
13.5%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 23.8% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.

Strategic Recommendations

✓ Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.

⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Art Unit 1641 - Prosecution Statistics Summary

Executive Summary

Art Unit 1641 is part of Group 1640 in Technology Center 1600. This art unit has examined 10,233 patent applications in our dataset, with an overall allowance rate of 56.0%. Applications typically reach final disposition in approximately 37 months.

Comparative Analysis

Art Unit 1641's allowance rate of 56.0% places it in the 11% percentile among all USPTO art units. This art unit has a significantly lower allowance rate than most art units at the USPTO.

Prosecution Patterns

Applications in Art Unit 1641 receive an average of 2.05 office actions before reaching final disposition (in the 70% percentile). The median prosecution time is 37 months (in the 13% percentile).

Strategic Considerations

When prosecuting applications in this art unit, consider the following:

  • The art unit's allowance rate suggests a more challenging examination environment compared to the USPTO average.
  • With more office actions than average, plan for relatively streamlined prosecution.
  • The median prosecution time is longer than average and should be factored into your continuation and client communication strategies.
  • Review individual examiner statistics within this art unit to identify examiners with particularly favorable or challenging prosecution patterns.

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.